{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:44:51Z","timestamp":1792457091812,"version":"4.5.0"},"reference-count":196,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>A dominant paradigm being developed in immunotherapy for hematologic malignancies is of adaptive immunotherapy that involves chimeric antigen receptor (CAR) T cells and bispecific T-cell engagers. CAR T-cell therapy has yielded results that surpass those of the existing salvage immunochemotherapy for patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL) after first-line immunochemotherapy, while offering a therapeutic option for patients with follicular lymphoma (FL) and mantle cell lymphoma (MCL). However, the role of the innate immune system has been shown to prolong CAR T-cell persistence. Cluster of differentiation (CD) 47-blocking antibodies, which are a promising therapeutic armamentarium for DLBCL, are novel innate immune checkpoint inhibitors that allow macrophages to phagocytose tumor cells. Intratumoral Toll-like receptor 9 agonist CpG oligodeoxynucleotide plays a pivotal role in FL, and vaccination may be required in MCL. Additionally, local stimulator of interferon gene agonists, which induce a systemic anti-lymphoma CD8+ T-cell response, and the costimulatory molecule 4-1BB\/CD137 or OX40\/CD134 agonistic antibodies represent attractive agents for dendritic cell activations, which subsequently, facilitates initiation of productive T-cell priming and NK cells. This review describes the exploitation of approaches that trigger innate immune activation for adaptive immune cells to operate maximally in the tumor microenvironment of these lymphomas.<\/jats:p>","DOI":"10.3390\/cancers14010141","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T02:31:27Z","timestamp":1640745087000},"page":"141","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment"],"prefix":"10.3390","volume":"14","author":[{"given":"Takashi","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu City 514-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2015","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.4049\/jimmunol.1001730","article-title":"Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction","volume":"185","author":"Rolf","year":"2010","journal-title":"J. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/annonc\/mdx189","article-title":"Unmet needs in the first-line treatment of follicular lymphoma","volume":"28","author":"Casulo","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: A single-center experience","volume":"10","author":"Mozas","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103038","DOI":"10.1016\/j.critrevonc.2020.103038","article-title":"Mantle cell lymphoma","volume":"153","author":"Cortelazzo","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated with High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chong, E.A., Alanio, C., Svoboda, J., Nasta, S.D., Landsburg, D.J., Lacey, S.F., Ruella, M., Bhattacharyya, S., Wherry, E.J., and Schuster, S.J. (2021). Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood.","DOI":"10.1182\/blood.2021012634"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","article-title":"Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma","volume":"32","author":"Levy","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In Situ Vaccination with a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I\/II Study","volume":"28","author":"Brody","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cencini, E., Fabbri, A., Sicuranza, A., Gozzetti, A., and Bocchia, M. (2021). The Role of Tumor-Associated Macrophages in Hematologic Malignancies. Cancers, 13.","DOI":"10.3390\/cancers13143597"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.aac9407","article-title":"Patrolling monocytes control tumor metastasis to the lung","volume":"350","author":"Hanna","year":"2015","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","article-title":"CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation","volume":"44","author":"Kumar","year":"2016","journal-title":"Immunity"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.1252510","article-title":"The cellular and molecular origin of tumor-associated macrophages","volume":"344","author":"Franklin","year":"2014","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","article-title":"Transcriptome-based network analysis reveals a spectrum model of human macrophage activation","volume":"40","author":"Xue","year":"2014","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2015.00212","article-title":"Anatomy of a Discovery: M1 and M2 Macrophages","volume":"6","author":"Mills","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"642285","DOI":"10.3389\/fimmu.2021.642285","article-title":"Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes","volume":"12","author":"Ricketts","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","article-title":"B-cell lymphomas present immunoglobulin neoantigens","volume":"133","author":"Khodadoust","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody","volume":"23","author":"Segal","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1078-0432.CCR-19-2973","article-title":"First-in-Human Study of Utomilumab, a 4-1BB\/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20(+) Non-Hodgkin Lymphomas","volume":"26","author":"Gopal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/s41598-018-20656-y","article-title":"Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking","volume":"8","author":"Turaj","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2018020040","article-title":"Enhancing immunotherapy of STING agonist for lymphoma in preclinical models","volume":"2","author":"Sallets","year":"2018","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/386181a0","article-title":"A family of proteins that inhibit signalling through tyrosine kinase receptors","volume":"386","author":"Kharitonenkov","year":"1997","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1128\/MCB.16.12.6887","article-title":"A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion","volume":"16","author":"Fujioka","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"22719","DOI":"10.1074\/jbc.273.35.22719","article-title":"High Expression of Inhibitory Receptor SHPS-1 and Its Association with Protein-tyrosine Phosphatase SHP-1 in Macrophages","volume":"273","author":"Veillette","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1074\/jbc.274.2.559","article-title":"Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule","volume":"274","author":"Jiang","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1126\/science.279.5350.509","article-title":"Rho GTPases and the Actin Cytoskeleton","volume":"279","author":"Hall","year":"1998","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/(SICI)1097-0169(1997)38:3<287::AID-CM7>3.0.CO;2-2","article-title":"Syk kinase, tyrosine-phosphorylated proteins and actin filaments accumulate at forming phagosomes during Fc gamma receptor-mediated phagocytosis","volume":"38","author":"Strzelecka","year":"1997","journal-title":"Cell Motil. Cytoskel."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1083\/jcb.200708043","article-title":"Inhibition of \u201cself\u201d engulfment through deactivation of myosin-II at the phagocytic synapse between human cells","volume":"180","author":"Tsai","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"13223","DOI":"10.1074\/jbc.273.21.13223","article-title":"Integrin-mediated Tyrosine Phosphorylation of SHPS-1 and Its Association with SHP-2","volume":"273","author":"Tsuda","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_57","first-page":"2130","article-title":"CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRP\u03b1 1","volume":"30","author":"Kee","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1182\/blood.V100.5.1852.h81702001852_1852_1859","article-title":"SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC","volume":"100","author":"Kant","year":"2002","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1016\/S0021-9258(17)41945-4","article-title":"Tyrosine Phosphorylation of the Gamma-Subunit of Fc(Gamma)-Receptors, P72(Syk), and Paxillin during Fc-Receptor-Mediated Phagocytosis in Macrophages","volume":"269","author":"Greenberg","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., and Volkmer, J. (2015). Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137345"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.molcel.2008.05.026","article-title":"Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47","volume":"31","author":"Hatherley","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRPalphaFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/30996","article-title":"Help for cytotoxic-T-cell responses is mediated by CD40 signalling","volume":"393","author":"Bennett","year":"1998","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40\u2013CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4049\/jimmunol.165.2.795","article-title":"Phenotypic and Functional Characterization of Mouse Hepatic CD8\u03b1+ Lymphoid-Related Dendritic Cells","volume":"165","author":"Morelli","year":"2000","journal-title":"J. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1084\/jem.20021542","article-title":"Presentation of Exogenous Antigens on Major Histocompatibility Complex (MHC) Class I and MHC Class II Molecules Is Differentially Regulated during Dendritic Cell Maturation","volume":"198","author":"Delamarre","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.4049\/jimmunol.172.8.4826","article-title":"Differential Requirement for the CD40-CD154 Costimulatory Pathway during Th Cell Priming by CD8\u03b1+and CD8\u03b1\u2212Murine Dendritic Cell Subsets","volume":"172","author":"Yasumi","year":"2004","journal-title":"J. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/2326-6066.CIR-19-0493","article-title":"CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity","volume":"8","author":"Fromm","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1038\/s41375-021-01201-9","article-title":"The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma","volume":"35","author":"Valero","year":"2021","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/s41375-019-0463-3","article-title":"CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages","volume":"33","author":"Papin","year":"2019","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","article-title":"Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma","volume":"73","author":"Song","year":"2013","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0002-9440(10)64255-1","article-title":"Tumor-Associated Macrophages Express Lymphatic Endothelial Growth Factors and Are Related to Peritumoral Lymphangiogenesis","volume":"161","author":"Schoppmann","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1172\/JCI26354","article-title":"The crucial role of macrophages in lymphangiogenesis","volume":"115","author":"Kerjaschki","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1172\/JCI23874","article-title":"Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages","volume":"115","author":"Maruyama","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2012.12.001","article-title":"Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis","volume":"38","author":"Yona","year":"2013","journal-title":"Immunity"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/2326-6066.CIR-19-0152","article-title":"Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia","volume":"7","author":"Banerjee","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ni.3818","article-title":"Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation","volume":"18","author":"Park","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/febs.14277","article-title":"A drug development perspective on targeting tumor-associated myeloid cells","volume":"285","author":"Majety","year":"2017","journal-title":"FEBS J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ptr.5958","article-title":"More insights into the pharmacological effects of artemisinin","volume":"32","author":"Zyad","year":"2017","journal-title":"Phytother. Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Mancuso, R.I., Saad, S.T.O., and Azambuja, H. (2021). Artesunate Switches Monocytes to an Inflammatory Phenotype with the Ability to Kill Leukemic Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020608"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","article-title":"Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients","volume":"99","author":"Timmerman","year":"2002","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1189\/jlb.69.1.81","article-title":"CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens","volume":"69","author":"Hartmann","year":"2001","journal-title":"J. Leukoc. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e20191712","DOI":"10.1084\/jem.20191712","article-title":"Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I\/II trial","volume":"217","author":"Frank","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood-2006-11-056168","article-title":"Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities","volume":"110","author":"Wolfl","year":"2007","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/2326-6066.CIR-17-0112","article-title":"Human Tumor Antigens Yesterday, Today, and Tomorrow","volume":"5","author":"Finn","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.1073\/pnas.96.16.9305","article-title":"CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells","volume":"96","author":"Hartmann","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.4049\/jimmunol.166.4.2291","article-title":"Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN","volume":"166","author":"Kadowaki","year":"2001","journal-title":"J. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1002\/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H","article-title":"Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12","volume":"31","author":"Krug","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1084\/jem.194.6.863","article-title":"Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens","volume":"194","author":"Kadowaki","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4049\/jimmunol.160.2.870","article-title":"CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen","volume":"160","author":"Davis","year":"1998","journal-title":"J. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/cimm.1999.1572","article-title":"Immunostimulatory DNA pre-priming: A novel approach for prolonged Th1-biased immunity","volume":"198","author":"Kobayashi","year":"1999","journal-title":"Cell Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4049\/jimmunol.164.2.944","article-title":"Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells","volume":"164","author":"Hartmann","year":"2000","journal-title":"J. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/BF01541318","article-title":"CpG DNA: A pathogenic factor in systemic lupus erythematosus?","volume":"15","author":"Krieg","year":"1995","journal-title":"J. Clin. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.4049\/jimmunol.161.6.3042","article-title":"Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA","volume":"161","author":"Jakob","year":"1998","journal-title":"J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8","article-title":"Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells","volume":"28","author":"Sparwasser","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U","article-title":"Identification of CpG oligonucleotide sequences with high induction of IFN-alpha\/beta in plasmacytoid dendritic cells","volume":"31","author":"Krug","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1016\/j.vaccine.2014.06.065","article-title":"Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer","volume":"32","author":"Scheiermann","year":"2014","journal-title":"Vaccine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative Expression of Toll-Like Receptor 1\u201310 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood-2002-11-3569","article-title":"A role for Toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells","volume":"101","author":"Bernasconi","year":"2003","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8754","DOI":"10.1158\/0008-5472.CAN-04-1691","article-title":"Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity","volume":"64","author":"Suzuki","year":"2004","journal-title":"Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1073\/pnas.161293498","article-title":"Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition","volume":"98","author":"Bauer","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","article-title":"CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity","volume":"186","author":"Chu","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nm0897-849","article-title":"Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants","volume":"3","author":"Roman","year":"1997","journal-title":"Nat. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"15553","DOI":"10.1073\/pnas.95.26.15553","article-title":"CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice","volume":"95","author":"Weeratna","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1073\/pnas.93.7.2879","article-title":"CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma","volume":"93","author":"Klinman","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.157.5.1840","article-title":"Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA","volume":"157","author":"Ballas","year":"1996","journal-title":"J. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.4049\/jimmunol.156.12.4570","article-title":"Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides","volume":"156","author":"Cowdery","year":"1996","journal-title":"J. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.4049\/jimmunol.162.11.6770","article-title":"Differential regulation of the IL-12 p40 promoter and of p40 secretion by CpG DNA and lipopolysaccharide","volume":"162","author":"Cowdery","year":"1999","journal-title":"J. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.0019-2805.2001.01350.x","article-title":"Activation of the immune system by bacterial CpG-DNA","volume":"105","author":"Hacker","year":"2002","journal-title":"Immunology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nature07486","article-title":"Memory CD8 T-cell compartment grows in size with immunological experience","volume":"457","author":"Vezys","year":"2008","journal-title":"Nature"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ni.1695","article-title":"Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells","volume":"10","author":"Guimond","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2009-06-227546","article-title":"Memories that last forever: Strategies for optimizing vaccine T-cell memory","volume":"115","author":"Ahlers","year":"2010","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Cockburn, I., Chen, Y.-C., Overstreet, M., Lees, J., Van Rooijen, N., Farber, D., and Zavala, F. (2010). Prolonged Antigen Presentation Is Required for Optimal CD8+ T Cell Responses against Malaria Liver Stage Parasites. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000877"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.4049\/jimmunol.147.6.1759","article-title":"Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA","volume":"147","author":"Messina","year":"1991","journal-title":"J. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1348-0421.1992.tb02102.x","article-title":"DNA from Bacteria, but Not from Vertebrates, Induces Interferons, Activates Natural Killer Cells and Inhibits Tumor Growth","volume":"36","author":"Yamamoto","year":"1992","journal-title":"Microbiol. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.4049\/jimmunol.157.5.2116","article-title":"Macrophages ingest and are activated by bacterial DNA","volume":"157","author":"Stacey","year":"1996","journal-title":"J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1073\/pnas.94.20.10833","article-title":"Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization","volume":"94","author":"Weiner","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U","article-title":"Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments","volume":"32","author":"Hacker","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.4049\/jimmunol.165.12.6889","article-title":"CpG DNA Induces Maturation of Dendritic Cells with Distinct Effects on Nascent and Recycling MHC-II Antigen-Processing Mechanisms","volume":"165","author":"Askew","year":"2000","journal-title":"J. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG Motifs in Bacterial DNA and Their Immune Effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"ref_130","first-page":"5595","article-title":"CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations","volume":"63","author":"Bevaart","year":"2003","journal-title":"Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nm0703-831","article-title":"CpG motifs: The active ingredient in bacterial extracts?","volume":"9","author":"Krieg","year":"2003","journal-title":"Nat. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.4049\/jimmunol.165.8.4165","article-title":"Phosphorothioate Backbone Modification Modulates Macrophage Activation by CpG DNA","volume":"165","author":"Sester","year":"2000","journal-title":"J. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.179.4.2493","article-title":"Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself","volume":"179","author":"Li","year":"2007","journal-title":"J. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.cji.0000211304.60126.8f","article-title":"Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients with Previously Treated Non-Hodgkin Lymphoma","volume":"29","author":"Link","year":"2006","journal-title":"J. Immunother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.4049\/jimmunol.0901941","article-title":"Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides","volume":"183","author":"Avalos","year":"2009","journal-title":"J. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1182\/blood.V89.8.2994","article-title":"Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma","volume":"89","author":"Wooldridge","year":"1997","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-07-0815","article-title":"Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin\u2019s lymphoma","volume":"13","author":"Leonard","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2004-06-2156","article-title":"Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: Increased interferon-alpha\/beta-inducible gene expression, without significant toxicity","volume":"105","author":"Friedberg","year":"2005","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2141.2009.07773.x","article-title":"Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma","volume":"146","author":"Friedberg","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood-2008-07-170274","article-title":"T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy","volume":"113","author":"Houot","year":"2009","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood-2014-08-593137","article-title":"Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma","volume":"125","author":"Kohrt","year":"2015","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canrad.2017.09.003","article-title":"Radiotherapy of relapse-refractory follicular lymphoma","volume":"22","author":"Grignano","year":"2018","journal-title":"Cancer Radiother."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Watanabe, T. (2021). The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105352"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1084\/jem.20062056","article-title":"Induced sensitization of tumor stroma leads to eradication of established cancer by T cells","volume":"204","author":"Zhang","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti\u2013CTLA-4 Antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon\u2013Dependent Innate and Adaptive Immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS(+)\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised Response Criteria for Malignant Lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"eaan4488","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous malignancy by local immunotherapy","volume":"10","author":"Czerwinski","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.beha.2017.10.006","article-title":"Pathogenesis of follicular lymphoma","volume":"31","author":"Lackraj","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Ma, M.C.J., Tadros, S., Bouska, A., Heavican, T., Yang, H., Deng, Q., Moore, D., Akhter, A., Hartert, K., and Jain, N. (2021). Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica.","DOI":"10.3324\/haematol.2020.274258"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.23460","article-title":"A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma","volume":"88","author":"Witzig","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_159","first-page":"932","article-title":"Biodistribution and Metabolism of Internally H-3 Labeled Oligonucleotides.1. Comparison of a Phosphodiester and a Phosphorothioate","volume":"45","author":"Sands","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.4049\/jimmunol.1900742","article-title":"Antibody Opsonization of a TLR9 Agonist\u2013Containing Virus-like Particle Enhances In Situ Immunization","volume":"204","author":"Blackwell","year":"2020","journal-title":"J. Immunol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1172\/JCI96061","article-title":"PD-L1 on host cells is essential for PD-L1 blockade\u2013mediated tumor regression","volume":"128","author":"Tang","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen\u2013Specific CD8+ T Cells Induced by Melanoma Vaccines","volume":"74","author":"Fourcade","year":"2013","journal-title":"Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2008-06-165654","article-title":"Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: A pilot study","volume":"113","author":"Zappasodi","year":"2009","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pathol-052016-100247","article-title":"Necroptosis: Mechanisms and Relevance to Disease","volume":"12","author":"Galluzzi","year":"2017","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.molcel.2019.09.006","article-title":"The Diversification of Cell Death and Immunity: Memento Mori","volume":"76","author":"Legrand","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e000337","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1158\/0008-5472.CAN-10-1825","article-title":"Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death","volume":"70","author":"Zappasodi","year":"2010","journal-title":"Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e1356964","DOI":"10.1080\/2162402X.2017.1356964","article-title":"Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy","volume":"6","author":"Montico","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4049\/jimmunol.1600262","article-title":"NK Cell Activation in the Antitumor Response Induced by IFN-\u03b1 Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients","volume":"197","author":"Lapenta","year":"2016","journal-title":"J. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(20)30358-6","article-title":"Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: Results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial","volume":"8","author":"Ladetto","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00262-019-02411-y","article-title":"Lenalidomide improves the therapeutic effect of an interferon-\u03b1-dendritic cell-based lymphoma vaccine","volume":"68","author":"Lapenta","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.cell.2013.08.014","article-title":"Cyclic Dinucleotides and the Innate Immune Response","volume":"154","author":"Danilchanka","year":"2013","journal-title":"Cell"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/eji.201445132","article-title":"TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN","volume":"45","author":"Temizoz","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","article-title":"Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors","volume":"76","author":"Baird","year":"2016","journal-title":"Cancer Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat. Med."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Melero, I., Gangadhar, T.C., Kohrt, H.E., Segal, N.H., Logan, T., Urba, W.J., Hodi, F.S., Ott, P.A., Perez-Gracia, J.L., and Wolchok, J.D. (2013). A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and\/or metastatic solid tumors and relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma (B-NHL). J. Clin. Oncol., 31.","DOI":"10.1200\/jco.2013.31.15_suppl.tps3107"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","article-title":"Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity","volume":"61","author":"Fisher","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev-immunol-030409-101243","article-title":"Control of Immunity by the TNFR-Related Molecule OX40 (CD134)","volume":"28","author":"Croft","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molimm.2017.01.006","article-title":"OX40: Structure and function\u2014What questions remain?","volume":"83","author":"Willoughby","year":"2017","journal-title":"Mol. Immunol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1074\/jbc.273.10.5808","article-title":"Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation","volume":"273","author":"Kawamata","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/MCB.18.1.558","article-title":"4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB","volume":"18","author":"Arch","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/ni1030","article-title":"The costimulation-regulated duration of PKB activation controls T cell longevity","volume":"5","author":"Song","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1073\/pnas.0600205103","article-title":"Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment","volume":"103","author":"So","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI64859","article-title":"Depleting tumor-specific Tregs at a single site eradicates disseminated tumors","volume":"123","author":"Marabelle","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1084\/jem.20071341","article-title":"OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection","volume":"205","author":"Piconese","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_193","first-page":"5514","article-title":"Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth","volume":"60","author":"Kjaergaard","year":"2000","journal-title":"Cancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1158\/0008-5472.CAN-07-6484","article-title":"OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor","volume":"68","author":"Gough","year":"2008","journal-title":"Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"E319","DOI":"10.1073\/pnas.1510518113","article-title":"Combination OX40 agonism\/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice","volume":"113","author":"Linch","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","article-title":"OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients","volume":"73","author":"Curti","year":"2013","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/141\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:55:04Z","timestamp":1760169304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":196,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["cancers14010141"],"URL":"https:\/\/doi.org\/10.3390\/cancers14010141","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}